Abstract
The functional architecture of the brain is composed of distinct networks, where higher system segregation, i.e. greater differentiation of such functional networks, is associated with better cognitive performance. Aging and many neurological diseases have been associated with reduced system segregation and thus cognitive impairment. The genetic basis and risk factors of system segregation are largely unknown. Here, we present the first genome-wide association study of fMRI-assessed system segregation in 16,635 UK Biobank participants, identifying nine independent genomic loci. The 66 implicated genes were significantly downregulated in brain tissue and upregulated in vascular tissue. Of major vascular risk factors (Life’s Simple 7), blood pressure showed a robust genetic correlation with system segregation. Observational and Mendelian randomization analyses confirmed a unfavourable effect of higher blood pressure on system segregation and of lower system segregation on cognition. Replication analyses in 2,414 Rotterdam Study participants supported these conclusions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was funded by DAAD post-doc fellowship (to JN), grants from the Alzheimer Forschung Initiative (AFI, Grant 15035 to ME), Legerlotz Stiftung (to ME), LMUexcellent (to ME); ZonMw Memorabel grant (project no 733050817 to MWV); European Union's Horizon 2020 research and innovation programme (grant agreement no. 667375 [CoSTREAM] to MWV and MD as well as grant agreement no. 666881 [SVDs@target] to MD); Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant for major research instrumentation (DFG, INST 409/193-1 FUGG; to MD), the DFG as part of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy - ID 390857198) and the CRC 1123 (B3) to MD); Walter Benjamin-fellowship (DFG, GE 3461/1-1 to MD), Hertie Foundation for Clinical Neurosciences (to NF); LMU Foerderung Forschung Lehre (Reg. 1032 to NF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank and the Rotterdam Study resources. Ethics approval for the UK Biobank study was obtained from the National Research Ethics Service Committee North West-Haydock (reference 11/NW/0382). The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG. We thank all participants and all other persons who contributed to data collection, management and distribution.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.